Scholarlink

<p>Glioblastoma (GBM) is an aggressive, immunotherapy-resistant brain tumor. Here, we engineered an oncolytic virus platform based on herpes simplex virus 1 for GBM viroimmunotherapy. We mutated the highly cytopathic MacIntyre strain to increase spread and oncolytic activity, limit genetic drift, prevent neuron infection and enable PET tracing. We incorporated microRNA target cassettes to attenuate replication in healthy brain cells. Moreover, we engineered the gD envelope protein to specifically target GBM using EGFR-specific or integrin-specific binders. Lastly, we incorporated five immunomodulators to remodel the tumor microenvironment (TME) by locally expressing IL-12, anti-PD1, a bispecific T cell engager, 15-hydroxyprostaglandin dehydrogenase and anti-TREM2 to target T cells and myeloid cells in the GBM TME. A single intratumoral injection increased survival in GBM preclinical models, while promoting tumor-specific T cell, natural killer cell and myeloid cell responses in the TME. In summary, we engineered a retargeted, safe and traceable oncolytic virus with strong cytotoxic and immunostimulatory activities for GBM immunotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy

  • 期刊论文

  • 发表日期：

    2025年12月4日

查看全文
  • Federico Giovannoni,
  • Craig A. Strathdee,
  • Camilo Faust Akl,
  • Brian M. Andersen,
  • Zhaorong Li,
  • Hong-Gyun Lee,
  • María Florencia Torti,
  • Joseph M. Rone,
  • Pere Duart-Abadia,
  • Martina Molgora,
  • Linxing Kong,
  • Michael Floyd,
  • Jian Teng,
  • Yulia Gyulakian,
  • Peter Grzesik,
  • Terry Farkaly,
  • Agnieszka Denslow,
  • Sonia Feau,
  • Irene Rodriguez-Sanchez,
  • Judith Jacques,
  • Marco Colonna,
  • Edward M. Kennedy,
  • Tooba Cheema,
  • Lorena Lerner,
  • Christophe Quéva,
  • Francisco J. Quintana

摘要

Glioblastoma (GBM) is an aggressive, immunotherapy-resistant brain tumor. Here, we engineered an oncolytic virus platform based on herpes simplex virus 1 for GBM viroimmunotherapy. We mutated the highly cytopathic MacIntyre strain to increase spread and oncolytic activity, limit genetic drift, prevent neuron infection and enable PET tracing. We incorporated microRNA target cassettes to attenuate replication in healthy brain cells. Moreover, we engineered the gD envelope protein to specifically target GBM using EGFR-specific or integrin-specific binders. Lastly, we incorporated five immunomodulators to remodel the tumor microenvironment (TME) by locally expressing IL-12, anti-PD1, a bispecific T cell engager, 15-hydroxyprostaglandin dehydrogenase and anti-TREM2 to target T cells and myeloid cells in the GBM TME. A single intratumoral injection increased survival in GBM preclinical models, while promoting tumor-specific T cell, natural killer cell and myeloid cell responses in the TME. In summary, we engineered a retargeted, safe and traceable oncolytic virus with strong cytotoxic and immunostimulatory activities for GBM immunotherapy.